A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells [0.03%]
吴茱萸碱通过介导TAF诱导的结肠上皮细胞EMT中磷酸化Smad2/3的作用在EMT逆转中的作用研究
Wanbin Yang,Xiuli Gong,Xiulian Wang et al.
Wanbin Yang et al.
Purpose Transdifferentiation exists within stromal cells in the tumour microenvironment. Transforming growth factor-β (TGF-β) secreted by tumour-associated fibroblasts (TAFs) affects the differentiation states of epithelial cells, includi...
Caffeic acid phenethyl ester exerts apoptotic and oxidative stress on human multiple myeloma cells [0.03%]
咖啡酸苯乙酯对人类多发性骨髓瘤细胞的促凋亡和氧化应激作用
Elizabeth Hernandez Marin,Hana Paek,Mei Li et al.
Elizabeth Hernandez Marin et al.
Caffeic acid phenethyl ester (CAPE) is a phenolic compound initially identified in bee glue. CAPE is reported to exhibit antitumor activity in many cancer models. However, the effect of CAPE on multiple myeloma (MM) is not well studied. We ...
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors [0.03%]
关于VLX600（一种铁螯合剂）在难治性晚期实体瘤患者中I期安全性和耐受性的研究
Kabir Mody,Aaron S Mansfield,Lalitha Vemireddy et al.
Kabir Mody et al.
Introduction VLX600 is a novel iron chelator designed to interfere with intracellular iron metabolism, leading to inhibition of mitochondrial respiration and bioenergetic catastrophe and resultant tumor cell death. Methods We conducted a mu...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):684-692. DOI:10.1007/s10637-018-0703-9 2019
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling [0.03%]
新型PI3K抑制剂S1通过Akt-S6信号途径与索拉非尼在非小细胞肺癌中的协同作用研究
Juan Wang,Shumei Ma,Xiuhua Chen et al.
Juan Wang et al.
Non-small cell lung cancer (NSCLC) has been the major cause of cancer-related deaths worldwide. Targeted therapy has been available as an additive strategy for NSCLC patients, but the inevitable resistance to mono-targeted agents has largel...
Laeeq Malik,David Lu
Laeeq Malik
Clinical trials in oncology have become increasingly complex because of incorporation of predictive biomarkers and patient selection based on molecular profiling of tumors. We have examined the change in procedures and work intensity in pha...
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors [0.03%]
plocabulin(AC-280923)治疗晚期实体瘤的I期临床试验
Elena Elez,Carlos Gomez-Roca,Arturo Soto Matos-Pita et al.
Elena Elez et al.
Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated dose-limiting toxicities (DLT) to define the maximum tolerated dose (MTD) and phase II rec...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):674-683. DOI:10.1007/s10637-018-0674-x 2019
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer [0.03%]
吉西他滨、S-1和LV联合治疗(GSL方案)晚期胰腺癌的Ⅱ期临床研究
Kei Saito,Hiroyuki Isayama,Yousuke Nakai et al.
Kei Saito et al.
Purpose Our previous phase I trial suggested feasibility of addition of leucovorin (LV) to S-1 and gemcitabine therapy in advanced pancreatic cancer. The aim of this phase II trial was to assess the efficacy and toxicity of gemcitabine, S-1...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):338-344. DOI:10.1007/s10637-018-0691-9 2019
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer [0.03%]
替西罗莫司与贝伐单抗治疗多西他赛耐药的转移性激素难治性前列腺癌患者I/II期临床研究
Pedro C Barata,Matthew Cooney,Prateek Mendiratta et al.
Pedro C Barata et al.
Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through vascular endothelial growth factor (VEGF) have been shown to play important roles in prostate cancer progression. Preclinical data in prostate cancer has sugge...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):331-337. DOI:10.1007/s10637-018-0687-5 2019
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors [0.03%]
一项开放性I期研究：口服[14C]-(MLN8237)阿西拉替布（Aurora A激酶抑制剂）在晚期实体瘤患者中的药动学、排泄及体内平衡研究
Xiaofei Zhou,Sandeepraj Pusalkar,Swapan K Chowdhury et al.
Xiaofei Zhou et al.
Aims This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics and safety of the investigational aurora A kinase inhibitor, alisertib, in three patients with advanced malignancies. Methods Part A; patients receive...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):666-673. DOI:10.1007/s10637-018-0693-7 2019
Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma [0.03%]
帕唑帕尼低脂饮食(PALM)方案治疗晚期肾细胞癌
Melissa A Reimers,Maryann M Shango,Stephanie Daignault-Newton et al.
Melissa A Reimers et al.
Background Pazopanib is approved for metastatic renal cell carcinoma (RCC). We assessed the safety and efficacy of pazopanib with a low fat meal (LFM):
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):323-330. DOI:10.1007/s10637-018-0692-8 2019